-
Infographic – 2022 Biotech Venture Funding Weakens
Venture funds for new U.S. biotechnology and pharmaceutical companies declined from historical highs in 2022, but a closer look reveals even more signs of financial tightening.
-
Environmental Biomarker Start-Up Gains $16M in Early Funds
A new company developing diagnostics for neurological and other disorders based on environmental exposures is raising $16 million in venture funds.
-
CEPI Assessing Advanced RNA Nanoparticle Vaccine
An international health organization is evaluating a new type of vaccine made with biodegradable RNA nanoparticles to help head off future viral pandemics.
-
Audio Digital Biomarkers Start-Up Raises $3.7M in Seed Funds
A new company developing techniques to analyze internal physiological sounds captured by stethoscopes as health indicators is raising $3.7 million in seed funds.
-
Nanotech Enzyme Process Boosts T-Cell Cancer Therapies
A bioengineering team devised techniques for feasibly adding cancer-killing enzymes to engineered immune cells that in lab mice kill solid-tumor and blood cancer cells.
-
Project to Sequence 20K Dog and Cat Genomes
Some 20,000 dogs and cats are expected to have their genomes sequenced in the next 10 years for a publicly available database to enable precision medicine for pets.
-
Infographic – Mixed Signals on 2022 Venture Funding
Total venture funds invested fell each quarter in 2022, from $163.1 billion in Q1 to $77.2 billion in Q4, which suggests continued declines into 2023.
-
Skills That Help When Starting a Business
There are plenty of businesses that set up great products, yet fail because the owners weren’t great at decision-making or properly marketing what they’ve got.
-
BioNTech to Provide Personal Cancer Immunotherapies in UK
The biotechnology company BioNTech SE is partnering with the U.K. government to provide up to 10,000 personalized cancer immunotherapy treatments by 2030.
-
Biotech Alliance Creating Circular RNA Cancer Drug
A partnership of biotechnology components and therapy companies aims to develop new drugs made from circular forms of RNA, starting with a colorectal cancer treatment.